Multidrug resistance in cancer (review)

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anticancer drug resistance is a significant challenge in cancer chemotherapy.
• P-glycoprotein (P-gp) overexpression in cancer cells confers a multidrug resistance (MDR) phenotype.
• P-gp functions as an efflux pump, reducing intracellular drug concentration and cytotoxicity.

Purpose of the Study:

• To explore the role of protein kinases in modulating P-glycoprotein activity and MDR.
• To investigate kinase-mediated phosphorylation and transcriptional regulation of P-gp.
• To identify potential therapeutic strategies for reversing MDR and enhancing anticancer drug efficacy.

Main Methods:

• Review of existing studies on protein kinase activators/inhibitors and P-glycoprotein.
• Analysis of research on the phosphorylation of P-glycoprotein.
• Examination of studies investigating the transcriptional regulation of the MDR1 gene by kinases.

Main Results:

• Protein kinase activators and inhibitors can modulate P-glycoprotein activity, often through phosphorylation.
• Some kinase modulators affect drug accumulation in MDR cells independently of their effects on P-gp phosphorylation.
• Protein kinase A (PKA) and protein kinase C (PKC) are implicated in the transcriptional regulation of the MDR1 gene.

Conclusions:

• Protein kinases are critical regulators of P-glycoprotein function and expression.
• Targeting these kinases presents a promising strategy for overcoming multidrug resistance in cancer.
• Further research into kinase pathways may lead to novel approaches to enhance anticancer drug effectiveness.